Revive Therapeutics Ltd. (RVVTF) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $3.16M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerRevive Therapeutics Ltd. (RVVTF) trades at $0.0071. Revive Therapeutics Ltd. is a pharmaceutical company focused on developing therapeutics for rare disorders and infectious diseases. Market cap: $3.16M, Sector: Healthcare.
Price as of · Last analyzed: Mar 15, 2026Analyst Coverage for RVVTF: RVVTF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Thousands of the 20,000+ US stocks here carry a MoonshotScore.
Scored companies in the same industry:
Revive Therapeutics Ltd. (RVVTF) Healthcare & Pipeline Overview
Revive Therapeutics Ltd. is a life sciences company focused on developing cannabinoid and psilocybin-based pharmaceuticals for rare inflammatory diseases and infectious diseases like COVID-19. Their lead drug candidate, Bucillamine, is in Phase 3 clinical trials, positioning the company within the specialty and generic drug manufacturing sector.
What Is the Investment Thesis for RVVTF?
Revive Therapeutics presents a high-risk, high-reward investment profile typical of early-stage pharmaceutical companies. The primary value driver is the successful completion of Phase 3 clinical trials for Bucillamine, targeting infectious diseases. Positive trial results could lead to regulatory approval and subsequent revenue generation. The company's research into psilocybin-based therapies for mental health disorders and substance abuse represents a longer-term growth opportunity. However, the company's small market capitalization of $3.16M and negative P/E ratio of -2.44 indicate significant financial risks. Investors should carefully consider the inherent uncertainties associated with drug development and regulatory approval processes.
Based on FMP financials and quantitative analysis
RVVTF Key Highlights
Bucillamine is currently in Phase 3 clinical trials for the treatment of infectious diseases, including COVID-19.
- The company has a cannabinoid pharmaceutical portfolio focused on rare inflammatory diseases.
- Revive Therapeutics has research collaboration agreements with multiple universities and PharmaTher Inc. to expand its drug development pipeline.
- The company is developing Psilocybin, which is in Phase 1 clinical study for treating methamphetamine use disorder.
- The company's market capitalization is $3.16M.
Who Are RVVTF's Competitors?
RVVTF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| CPIVF Captiva Verde Wellness Corp. | $0.10 | 0.00% | $30.5M | — |
| YCBD cbdMD, Inc. | $0.38 | +1.42% | $5.10M | — |
| AKAN Akanda Corp. | $3.43 | -14.89% | $9.05M | — |
| QNTM Quantum BioPharma Ltd. | $1.42 | -6.58% | $9.13M | 30 5-pillar |
| IMCC IM Cannabis Corp. | $0.54 | +8.49% | — | |
| BFRI Biofrontera Inc. | $0.60 | +1.10% | $10.8M | — |
| COSM COSM | $2.95 | +3.51% | $14.8M | — |
| SHPH Shuttle Pharmaceuticals Holdings, Inc. | $3.90 | +2.01% | $18.6M | 32 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RVVTF's Key Strengths?
Promising drug pipeline with Bucillamine in Phase 3 trials.
- Focus on unmet medical needs in rare disorders and infectious diseases.
- Strategic research collaborations with universities and PharmaTher Inc.
- Development of both cannabinoid and psilocybin-based therapeutics.
What Are RVVTF's Weaknesses?
Limited financial resources and small market capitalization.
- Dependence on successful clinical trial outcomes and regulatory approvals.
- Early-stage development of psilocybin-based therapies.
- Small number of employees.
What Are the Key Risks for RVVTF?
Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Failure to obtain regulatory approval for Bucillamine or other drug candidates.
- Unfavorable clinical trial results.
- Competition from larger pharmaceutical companies with greater resources.
- Dependence on securing additional funding to support research and development.
- Changes in government regulations regarding cannabinoid and psilocybin-based therapies.
What Are RVVTF's Competitive Advantages?
- Proprietary drug formulations and intellectual property.
- Research collaborations with leading universities and research institutions.
- Focus on niche markets with unmet medical needs.
- Advanced stage clinical trials for lead drug candidate, Bucillamine.
What Does RVVTF Do?
Revive Therapeutics Ltd., incorporated in 2012 and headquartered in Toronto, Canada, is a life sciences company dedicated to the research and development of novel therapeutics for rare disorders and infectious diseases. The company's primary focus is on developing treatments utilizing cannabinoid and psilocybin-based pharmaceuticals. Revive's pipeline includes Bucillamine, a drug in Phase 3 clinical trials for infectious diseases, including influenza and COVID-19. Additionally, the company is developing Psilocybin, currently in Phase 1 clinical study, for treating methamphetamine use disorder. Further research is being conducted on Psilocin for mental health conditions such as depression, anxiety, bipolar disorder, bulimia, and anorexia nervosa. The company is also exploring cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation. Revive Therapeutics collaborates with PharmaTher Inc., North Carolina State University, University of California, San Francisco, and University of Health Sciences Antigua to advance its research and development efforts. These collaborations focus on areas such as psilocybin development for cancer treatment, biosynthetic psilocybin production, Bucillamine's potential for treating severe COVID-19, and clinical research of psychedelics.
What Products and Services Does RVVTF Offer?
- Researches and develops therapeutics for rare disorders.
- Focuses on treatments for infectious diseases.
- Offers a cannabinoid pharmaceutical portfolio.
- Develops Bucillamine for infectious diseases, including COVID-19.
- Develops Psilocybin for treating methamphetamine use disorder.
- Researches Psilocin for mental health conditions.
- Explores cannabidiol for autoimmune hepatitis and organ transplantation injury.
How Does RVVTF Make Money?
- Develops pharmaceutical products through in-house research and development.
- Collaborates with universities and other research institutions to advance drug development.
- Seeks regulatory approval for its drug candidates.
- Plans to commercialize approved drugs through partnerships or direct sales.
What Industry Does RVVTF Operate In?
Revive Therapeutics operates within the specialty and generic drug manufacturing industry, a sector characterized by intense competition and stringent regulatory requirements. The industry is driven by the constant need for new and improved treatments for various diseases. Companies like Revive Therapeutics focus on niche markets, such as rare disorders and infectious diseases, to differentiate themselves. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms, all vying for market share. The development of novel therapies, particularly in areas like mental health and substance abuse, represents a significant growth opportunity within the industry.
Who Are RVVTF's Key Customers?
- Patients suffering from rare disorders.
- Patients with infectious diseases, including COVID-19.
- Individuals with methamphetamine use disorder.
- Patients with mental health conditions such as depression and anxiety.
- Individuals with autoimmune hepatitis.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Revive Therapeutics Ltd. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Toronto, Canada.
How Revive Therapeutics Ltd. Is Valued
Revive Therapeutics Ltd. carries a market capitalization of $3.16M, placing it in the micro-cap category.
Key Financial Metrics
Return on equity for Revive Therapeutics Ltd. stands at 26.8%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -1.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.04 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -11.7%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Revive Therapeutics Ltd.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
RVVTF Latest News
No recent news available for RVVTF.
RVVTF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for RVVTF.
Price Targets
Wall Street price target analysis for RVVTF.
RVVTF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for RVVTF; grades run from A+ (80-100) to F (below 30).
Leadership: Michael Frank
CEO
Michael Frank serves as the CEO of Revive Therapeutics Ltd. His background includes experience in managing and leading small teams within the life sciences sector. He is responsible for overseeing the company's research and development efforts, strategic partnerships, and overall corporate strategy. His leadership is focused on advancing the company's drug pipeline and securing regulatory approvals.
Track Record: Under Michael Frank's leadership, Revive Therapeutics has advanced Bucillamine to Phase 3 clinical trials for infectious diseases. He has also overseen the expansion of the company's research into psilocybin-based therapies and the establishment of strategic collaborations with universities and PharmaTher Inc. His focus has been on driving the company's drug development programs forward.
RVVTF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Revive Therapeutics may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting and oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries a higher degree of risk due to the potential for less transparency and liquidity.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Lower liquidity and higher price volatility.
- Potential for pump-and-dump schemes and other fraudulent activities.
- Greater risk of delisting or trading suspensions.
- Limited regulatory oversight compared to major exchanges.
- Verify the company's financial statements and SEC filings (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Review the company's capitalization structure and potential dilution.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Understand the risks associated with OTC investments.
- Phase 3 clinical trials for Bucillamine.
- Research collaborations with reputable universities.
- Focus on developing therapeutics for unmet medical needs.
- Company incorporated in 2012.
Common Questions About RVVTF (Healthcare)
What does Revive Therapeutics Ltd. do?
Revive Therapeutics Ltd. is a life sciences company focused on the research, development, and commercialization of novel therapeutics for rare disorders and infectious diseases.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.